Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure

PHASE3TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Systolic Heart Failure
Interventions
DRUG

Placebo

"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"

DRUG

Udenafil (Zydena)

Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

lead

Seoul National University Hospital

OTHER